Fresenius makes use of the relief payments for increased energy costs provided for in the Hospital Financing Act
Today, the Fresenius Management Board has decided to make use of the compensation and reimbursement payments for German hospitals in the amount of up to €300 million (from the current perspective) provided for by the "Energy Relief Package" (“Entlastungspaket Energiehilfen“) under the Hospital Financing Act (“Krankenhausfinanzierungsgesetz”) to cover increased energy costs.
Fresenius successfully completes deconsolidation of Fresenius Medical Care
Fresenius has successfully completed the deconsolidation of Fresenius Medical Care: The change in legal form was entered in the commercial register on November 30, 2023, and thereby took effect after the Senate of the Bamberg Higher Regional Court had granted Fresenius Medical Care's applications for approval in full.
Fresenius Medical Care enters into favorable settlement agreement with U. S. government with positive earnings impact of approx. EUR 175 million – 2023 earnings outlook raised
Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, resolved a legal dispute with the U.S. government, for accounts receivable in legal dispute, and entered into a final and legally binding settlement agreement today, whereby the company will receive a payment from the U.S. government.
November 21, 2023 · Fresenius Medical Care
Brief News
Fresenius Kabi advances with Vision 2026 – progress on streamlining of production network
Fresenius Kabi is further executing on its Vision 2026 strategy: The company and the Prange Group today have signed an agreement to transfer the ownership of Fresenius Kabi's plant in Halden, Norway, to HP Halden Pharma AS, a company of the Prange Group. The Prange Group, together with its affiliate Adragos Pharma, take over the plant with equipment as well as full staff and will continue the manufacturing of Fresenius Kabi’s products. This is another step to reduce complexity and optimize utilization in its global manufacturing network.
#FutureFresenius continues to provide positive momentum: Fresenius delivers strong third quarter performance and improves operating earnings outlook
Michael Sen, CEO of Fresenius: “Fresenius had a great 3rd Quarter 2023. We made progress on every part of our #FutureFresenius program, including simplification of our corporate structure, and achieved cost savings well ahead of our targets for the full year 2023.
Fresenius Medical Care continues to execute on turnaround plan and raises 2023 earnings outlook
Helen Giza, Chief Executive Officer of Fresenius Medical Care, said: “Our unwavering focus on executing against our strategic plan and the successful implementation of turnaround measures to date, continue to translate into improved operating performance.
November 01, 2023 · Fresenius Medical Care
Brief News
Fresenius Kabi launches Tyenne®*, the first approved tocilizumab biosimilar in the European Union
Fresenius Kabi announced today the launch of its tocilizumab biosimilar Tyenne® referencing RoActemra®** (tocilizumab) in the European Union.
Tyenne® becomes the first tocilizumab biosimilar available in Europe for the treatment of several inflammatory and immune diseases.
Tyenne® is Fresenius Kabi’s third approved biosimilar launched in Europe, offering patients and heath care providers a flexible range of user-friendly subcutaneous (prefilled syringe and autoinjector) and intravenous (vials) administration.
* Tyenne® (tocilizumab) is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries.
** RoActemra® is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group.
Fresenius Medical Care Demonstrates Commitment to Innovating Dialysis and Kidney Disease Care with Presentations at the American Society of Nephrology (ASN) Kidney Week 2023
October 31, 2023 · Fresenius Medical Care
Brief News
Fresenius exits hospital market in Peru
Fresenius sells its 70 percent stake in IDCQ CRP, a co-holding entity of the hospital Clínica Ricardo Palma in Lima, Peru. The stake is acquired by entities of the Verme family which already hold a stake in the hospital, together with other local investors. This exit from the hospital market in Peru is a further step to strengthening #FutureFresenius and is in line with the company's intention to divest certain assets announced earlier this year. Subject to antitrust review, the all-cash transaction is expected to close in the first quarter of 2024.
Fresenius Medical Care Achieves Key AI Milestone With First-Phase Completion of Largest Global Dialysis Clinical Dataset
October 26, 2023 · Fresenius Medical Care
Brief News
Fresenius Kabi Named “Supplier Partner of the Year 2023” by Vizient
Fresenius Kabi has been named the 2023 Supplier Partner of the Year by Vizient, Inc., the largest U.S. provider of healthcare performance improvement services. This recognition reflects Fresenius Kabi’s commitment to collaboration and innovation to enhance quality of care and patient safety.
This is Fresenius Kabi’s second time being named Vizient’s Supplier Partner of the Year.
October 04, 2023 · Fresenius Kabi
Brief News
EMA has accepted marketing authorization application for Ustekinumab biosimilar candidate of Fresenius Kabi and Formycon
Fresenius Kabi and its license partner Formycon announced today that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for FYB202, an Ustekinumab biosimilar candidate. FYB202 references Johnson & Johnson’s Stelara®*, a human monoclonal antibody for the treatment of immune-mediated disorders.
Fresenius Kabi is the commercialization partner. The acceptance of the MAA for review marks another milestone in the company’s Vision 2026 growth strategy.
For more information, please see the website of Fresenius Kabi.
* Stelara® is a registered trademark of Johnson & Johnson
September 29, 2023 · Fresenius Kabi
Brief News
Fresenius supports people affected by the earthquake in Morocco and flooding in Libya
Fresenius makes available €500.000 for immediate release to the German Red Cross (Deutsches Rotes Kreuz e.V.) as assistance for disaster relief efforts to people affected by the recent earthquake in Morocco and the flooding in Libya. This cash donation will support direct disaster relief efforts on site. In addition, Fresenius remains committed to providing assistance with much needed medical products from its own product portfolio in crisis situations.
September 28, 2023 · Fresenius
Brief News
mAbxience and Abbott enter strategic partnership
mAbxience, a Fresenius Kabi majority-owned Group, today announced a strategic partnership with Abbott to commercialize several biosimilars focusing on oncology, women’s health and respiratory diseases in emerging markets including Latin America, Southeast Asia, the Middle East, and Africa. The first molecules are expected to be launched in 2025. mAbxience will manufacture the biosimilars in its state-of-the art and Good Manufacturing Practices (GMP)-approved facilities in Spain and Argentina. Additionally, mAbxience will be responsible for driving the clinical milestones for some of the molecules still undergoing development. The biosimilars will be commercialized by Abbott.
This strategic partnership strengthens mAbxience’s global presence and expands access to cutting-edge healthcare solutions in underserved regions.
September 20, 2023 · Fresenius Kabi
Brief News
Fresenius Kabi’s biosimilar Tyenne®* becomes first tocilizumab biosimilar approved by the European Commission
The European Commission (EC) has approved Fresenius Kabi’s tocilizumab biosimilar Tyenne®*. It is the first tocilizumab biosimilar approved by the EC and Fresenius Kabi’s third approved biosimilar in Europe. This approval is another crucial milestone in the company’s Vision 2026 growth strategy.
* Tyenne® (tocilizumab) is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries.
September 19, 2023 · Fresenius Kabi
Brief News
Key parameter for the 2024 DRG inflator for German hospitals set at 4.22%
The rate of change, a key parameter for determining the price increase for the reimbursement of hospital treatments in 2024 in Germany, has been set at 4.22%. Due to cost inflation, the rate of change will most likely mark the lower limit of the price increase for hospital treatments for 2024 in Germany. The change in hospital costs is the other parameter used in the annual determination of the reimbursement increase. The final DRG inflator should be determined at the latest by the end of the year.